Study To Assess The Safety And Efficacy Of The Tempsure Flexsure Applicators For Abdominal Wrinkles

NCT04930705 | Terminated FDA Device

• 1 other identifier: 7027-PL01-2021
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Subjects will be enrolled at 1 study center. Subjects may receive 5 treatments with the TempSure® device on the abdomen for wrinkles.

Conditions

Wrinkle

Outcome Measures

Primary Outcomes (2)

• Correct Identification of Pre-Treatment Images Compared to Follow Up Images

  Blinded independent reviewers will be given pre-treatment and 30 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.

  30 Day Follow Up

• Correct Identification of Pre-Treatment Images Compared to Follow Up Images

  Blinded independent reviewers will be given pre-treatment and 90 day follow up images and will identify which image is pre-treatment, and which image was taken at the follow up. The percentage of correct images identified will be reported.

  90 Day Follow Up

Study Arms (1)

TempSure FlexSure Applicator

EXPERIMENTAL

Subjects will be treated with the TempSure FlexSure applicator device at each treatment.

Device: Treatment with TempSure Applicator

Interventions

Treatment with TempSure Applicator DEVICE

Subjects will receive up to 5 treatments on the abdomen.

TempSure FlexSure Applicator

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• A healthy, non-smoking male or female between the age of 18 - 55 years old.
• Willing to receive treatments with the TempSure® device.
• Understand and accept obligation not to receive any other procedures on the treatment and control area throughout the length of the study.
• Understands and accepts the obligation and is logistically able to be present for all visits.
• Is willing to comply with all requirements of the study and sign the informed consent document.

You may not qualify if:

• Is pregnant or of child bearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
• The subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months prior to entering this study.
• The subject has a cut, wound, or infected skin on the area to be treated.
• The subject is on local, oral, or systemic anesthetic agents.
• The subject has nerve insensitivity to heat in the treatment area.
• The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
• Cautionary Criteria:
• The subject has any embedded electronic device that gives or receives a signal, the device should be turned off or removed prior to treatment.
• The subject has an embedded pacemaker or implantable cardioverter defibrillator (ICD), the client's cardiologist must be consulted prior to treatment.
• NOTE: This device has not been tested on patients implanted with electronic devices that receive or emit signals, such as: Pacemakers, Implantable Cardiac Defibrillators (ICD), or Cardiac Resynchronization Therapy (CRT) devices.
• If the neutral pad would need to be placed on a subject that has a metal plate, rod, or any metal implant that could conduct heat from the Smart Handpiece or surgical handpiece.
• The subject is allergic to adhesives, such as glues on medical tape, they should be alerted that a rash may occur on the neutral pad site and an over the counter solution may be used to treat the area.
• If the subject has an unhealthy expectation of the results - this is not plastic surgery and all subject should be fully informed of the treatment's expected results.
• The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated - this treatment will be ineffective.
• The subject has used Accutane (Isotretinoin) six to twelve months prior to treatment, as this can thin the skin and make it britlle

Sponsors & Collaborators

• Cynosure, Inc.: lead

Study Sites (1)

JUVA Skin & Laser Center

New York, New York, 10022, United States

Location

MeSH Terms

Interventions

Therapeutics

Study Officials

• Jennifer Civiok

  Cynosure, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2021
• First Posted: June 18, 2021
• Study Start: May 17, 2021
• Primary Completion: May 31, 2022
• Study Completion: May 31, 2022
• Last Updated: October 7, 2022

Record last verified: 2022-10

Locations

US (1)